Drug Trial Radar · NCT04101578
Clinical Prognosis and Progression of Myasthenia Gravis Patients
Last checked: Nov 20, 2026Latest source record: Aug 23, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
2,000
Planned (sponsor's estimate)
Start
Feb 8, 2017
Primary completion
Jun 1, 2023
Study completion Dec 31, 2024
Sponsor
- Lead sponsor
- Da, Yuwei, M.D.Individual
- Sponsor type
- Individual
- First posted
- Sep 24, 2019
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 15 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study collects the clinical data of myasthenia gravis (MG) patients, assesses outcomes and adverse effects of different treatment regimens, and searches for risk factors of conversion to generalized MG.
Conditions
- Myasthenia Gravis
Interventions
Symptomatic Treatment, Steroids, Immunosuppressive Agents, Plasma Exchange(PE), Intravenous Immunoglobulin(IVIg)Drug
Treatment regimens are determined according to the physician's judgment and preferences of the patients.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Conversion rates from ocular to generalized MG at the last visit and risk factors.Time frame: Baseline, 48 months
- Change in Quantitative Myasthenia Gravis (QMG) Scores from Baseline to 48 months.Time frame: Baseline, 12 months, 24 months, 36 months, 48 months
- Change in MG-specific Activities of Daily Living scale (MG-ADL).Time frame: Baseline,3months, 6 months, 9 months, 12 months, 18 months, 24 months, 30months, 36 months, 42 months, 48 months
- The proportion of patients reaching minimal manifestations (MM) or better.Time frame: 48 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Xuan Wu Hospital, Capital Medical University
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.